Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression

[1]  C. Drake,et al.  TGM4: an immunogenic prostate-restricted antigen , 2021, Journal for ImmunoTherapy of Cancer.

[2]  M. Rubin,et al.  A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance , 2020, Nature Cancer.

[3]  P. Hegde,et al.  High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade , 2020, Nature Medicine.

[4]  Hongyu Zhao,et al.  Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors , 2020, Nature Medicine.

[5]  A. Partin,et al.  T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer , 2020, Clinical Cancer Research.

[6]  R. Bryant,et al.  Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study. , 2020, European urology.

[7]  C. Drake,et al.  Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen , 2020, Oncoimmunology.

[8]  K. Kessenbrock,et al.  Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics , 2019, Science Immunology.

[9]  C. Drake,et al.  Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. G. van der Poel,et al.  Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐ and CXCL8‐mediated cancer cell migration , 2018, Molecular oncology.

[11]  S. Barry,et al.  IL-23 secreted by myeloid cells drives castration-resistant prostate cancer , 2018, Nature.

[12]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[13]  C. Drake,et al.  Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model , 2017, Prostate Cancer and Prostatic Diseases.

[14]  Chunsheng Zhang,et al.  Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. , 2017, Cancer cell.

[15]  C. Drake,et al.  Combining Intra-Tumoral Treg Depletion with Androgen Deprivation Therapy (ADT): Pre-Clinical Activity in the Myc-CaP Model , 2017, Prostate Cancer and Prostatic Diseases.

[16]  C. Drake,et al.  Myeloid‐derived cells in prostate cancer progression: phenotype and prospective therapies , 2017, Journal of leukocyte biology.

[17]  A. Partin,et al.  Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). , 2017 .

[18]  I. Wistuba,et al.  VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.

[19]  O. Elemento,et al.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. , 2017, Cancer discovery.

[20]  R. DePinho,et al.  Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer , 2017, Nature.

[21]  E. Niskanen,et al.  Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome , 2016, Nucleic acids research.

[22]  F. Saad,et al.  Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Duane H. Hamilton,et al.  The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance , 2016, Vaccines.

[24]  Aaron T. L. Lun,et al.  From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline , 2016, F1000Research.

[25]  I. Melero,et al.  Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs) , 2016, Clinical Cancer Research.

[26]  Yi Xiao,et al.  Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer , 2016, Medicine.

[27]  Dakang Xu,et al.  Telomerase Deficiency Causes Alveolar Stem Cell Senescence-associated Low-grade Inflammation in Lungs* , 2015, The Journal of Biological Chemistry.

[28]  Henry W. Long,et al.  The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.

[29]  T. Yamanaka,et al.  Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy , 2015, Oncotarget.

[30]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[31]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[32]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[33]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[34]  Charles P. Lin,et al.  Tracking Single Cells in Live Animals Using a Photoconvertible Near-Infrared Cell Membrane Label , 2013, PloS one.

[35]  R. Cardiff,et al.  ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer , 2013, Proceedings of the National Academy of Sciences.

[36]  C. Bieberich,et al.  A Hoxb13‐driven reverse tetracycline transactivator system for conditional gene expression in the prostate , 2012, The Prostate.

[37]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[38]  Mark R. Johnson,et al.  NFκB and AP-1 Drive Human Myometrial IL8 Expression , 2012, Mediators of inflammation.

[39]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[40]  C. Drake.  Prostate cancer as a model for tumour immunotherapy , 2010, Nature Reviews Immunology.

[41]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[42]  Martin J. Aryee,et al.  Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.

[43]  G. Haraldsen,et al.  The murine IL‐8 homologues KC, MIP‐2, and LIX are found in endothelial cytoplasmic granules but not in Weibel‐Palade bodies , 2010, Journal of leukocyte biology.

[44]  Julia A. Lasserre,et al.  Histone modification levels are predictive for gene expression , 2010, Proceedings of the National Academy of Sciences.

[45]  A. Mes-Masson,et al.  Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. , 2009, Journal of immunological methods.

[46]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[47]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[48]  R. Lorenz,et al.  Expression of CXCL15 (Lungkine) in Murine Gastrointestinal, Urogenital, and Endocrine Organs , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[49]  C. Sawyers,et al.  Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. , 2005, Cancer research.

[50]  R. Agarwala,et al.  Protein database searches using compositionally adjusted substitution matrices , 2005, The FEBS journal.

[51]  C. Drake,et al.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. , 2005, Cancer cell.

[52]  Jonathan Pevsner,et al.  Bioinformatics and functional genomics , 2003 .

[53]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[54]  M. T. Moser,et al.  T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[55]  P. Bennett,et al.  Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. , 2001, Molecular human reproduction.

[56]  Martin R. Schneider,et al.  Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.

[57]  S. Menon,et al.  Lungkine, a novel CXC chemokine, specifically expressed by lung bronchoepithelial cells. , 1999, Journal of immunology.

[58]  Michael A. Fiedler,et al.  Inhibition of TNF- α -induced NF- κ B Activation and IL-8 Release in A549 Cells with the Proteasome Inhibitor MG-132 , 1998 .

[59]  E. Niskanen,et al.  to reprogram the prostate cancer cell transcriptome , 2022 .